Greg has more than 25 years of small molecule drug discovery and development experience in a diverse range of disease areas.

Prior to joining Auransa Greg held leadership roles at Scios, Inc. (acquired by Johnson and Johnson) and Sai Life Sciences. While at Scios he was the Research Team Leader for their p38 kinase inhibitor program, which advanced two molecules into clinical trials (SCIO-469 and SCIO-323). At Sai Life Sciences he helped to establish their medicinal chemistry facility in Pune, India, managing 175 chemists engaged in a variety of drug discovery projects for global biotech and pharma companies. These outsourced drug discovery collaborations led to the advancement of numerous preclinical candidates.

Greg received his PhD in organic chemistry from Montana State University and completed a postdoctoral fellowship at Stanford University under the tutelage of Prof. W. S. Johnson.